The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis.

about

The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis.

Item

http://www.wikidata.org/entity/Q55025570

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@en

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@nl

type

Item

label

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@en

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@nl

prefLabel

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@en

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@nl

P1476

The Wilms' tumor gene-1 is a p ...... tic syndrome: a meta analysis.

@en

P2093

Jinhuan Wang

http://www.w3.org/2001/XMLSchema#string

Lin Liu

http://www.w3.org/2001/XMLSchema#string

Yanan Jiang

http://www.w3.org/2001/XMLSchema#string

Zeng Cao

http://www.w3.org/2001/XMLSchema#string

Zhigang Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

International scoring system for evaluating prognosis in myelodysplastic syndromes

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.

Clinical effect of point mutations in myelodysplastic syndromes

Myelodysplasia.

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Revised international prognostic scoring system for myelodysplastic syndromes.

WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.

Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing

The evolution of hematopoietic SCT in myelodysplastic syndrome.

P304

16205-16212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23671

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29662637

http://www.w3.org/2001/XMLSchema#string

P932

5882328

http://www.w3.org/2001/XMLSchema#string